Abstract 1512P
Background
Life expectancy has currently increased and pancreaticoduodenectomy (PD) is being performed more frequently on elderly patients in Japan. Surgical treatment for pancreatic ductal adenocarcinoma (PDAC) in patients over 80 years old is increasingly accepted, although it may lead to a decline in quality of life after surgery. Currently, there are no definitive indications for PD in octogenarians. This study aims to examine the surgical indications for PD in this age group, focusing on clinical background and perioperative and postoperative outcomes.
Methods
This retrospective analysis included patients with PDAC who underwent PD between 2012 and 2022. Patients aged ≥80 years were categorized as the Elderly (E) group, while those <80 years were classified as the Non-elderly (N) group. We compared clinical backgrounds, perioperative, and postoperative outcomes between the groups.
Results
PD was performed on 147 patients with PDAC. The median age was 71 years (range 45-85). Twenty-two patients (15.0%) were in the E group and 125 (85.0%) in the N group. The median Charlson comorbidity index (CCI) was significantly higher in the E group (6, range 5-10) compared to the N group (4, range 1-11; p
Conclusions
PD could be safely performed in elderly patients in good physical condition, with the survival benefit of PD for PDAC appearing as promising in elderly patients as in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Keio University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18